Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron

Executive Summary

Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.

Advertisement

Related Content

Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
Exscientia Bags Roche As AI Partner And $26m Series B To Fund Own Pipeline
Biotech Deals Stand Out In 2018 Korean Licensing Trends
Oculis Eyes Opportunities With Fresh Funding and Novartis Licensing Deal
Sanofi Takes €80M BioNTech Stake & Extends 2015 Deal
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
With Dicerna's NASH Asset, Boehringer Found What It Was Looking For
Stealthy NGM And Bristol Emerge As Serious NASH Competitors

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel